AIM ImmunoTech (AIM) Total Current Liabilities (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Total Current Liabilities came in at $6.1 million in Q1 2026, down 37.08% YoY from $9.8 million in Q1 2025, and down 1.27% on a QoQ basis from $6.2 million in Q4 2025.
AIM ImmunoTech (AIM) Total Current Liabilities (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Total Current Liabilities data on file, last reported at $6.1 million in Q1 2026.
- Quarterly Total Current Liabilities fell 37.08% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 37.08% YoY) and the FY2025 annual result came in at $6.2 million, down 34.72% from the prior year.
- Total Current Liabilities eased to $6.1 million in Q1 2026, from $6.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $10.4 million in Q2 2025 to a low of $766000.0 in Q1 2022.
- A 5-year average of $5.8 million and a median of $6.1 million in 2026 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 535.71% — and 2025, when it tumbled 59.97%.
- Tracing AIM's Total Current Liabilities over 5 years: stood at $1.4 million in 2022, then surged by 535.71% to $8.7 million in 2023, then grew by 10.21% to $9.5 million in 2024, then slumped by 34.72% to $6.2 million in 2025, then decreased by 1.27% to $6.1 million in 2026.
- The last three Total Current Liabilities figures came in at $6.1 million (Q1 2026), $6.2 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | 4.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.95 Mn |
| Mar 31, 2026 | 6.15 Mn |
| Dec 31, 2025 | 6.22 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 10.39 Mn |
| Mar 31, 2025 | 9.77 Mn |
| Dec 31, 2024 | 9.54 Mn |
| Sep 30, 2024 | 10.10 Mn |
| Jun 30, 2024 | 8.84 Mn |
| Mar 31, 2024 | 9.88 Mn |
| Dec 31, 2023 | 8.65 Mn |
| Sep 30, 2023 | 4.72 Mn |
| Jun 30, 2023 | 2.89 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 1.36 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 1.37 Mn |
| Mar 31, 2022 | 766,000.00 |
| Dec 31, 2021 | 673,000.00 |
| Sep 30, 2021 | 767,000.00 |